Longeveron Inc was incorporated as a Delaware limited liability company on October 9, 2014 and was authorized to operate in Florida on December 15, 2014. The company is a clinical-stage biotechnology company that develops regenerative medicines to meet unmet medical needs. The company's main research product is Lomecel-B brand MSCs, an allogeneic drug signaling cell (MSC) therapeutic product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has a variety of modes of action, including pro-vascular, pro-regeneration and anti-inflammatory mechanisms, promoting tissue repair and healing, and has a wide range of potential applications in a range of disease fields. The company is currently developing three clinical indications: Left Heart Hypoplasia Syndrome (HLHS), aging-related weakness and Alzheimer's disease (AD).